The CCT7 gene encodes the eta subunit of the Chaperonin Containing TCP1 (CCT) complex, also known as TRiC (TCP-1 Ring Complex). CCT7 is one of eight distinct subunits that comprise this essential hetero-oligomeric chaperone system required for the proper folding of cytoskeletal proteins including actin and tubulin[1].
The CCT complex represents the primary cytosolic chaperone system in eukaryotes, essential for maintaining proteostasis in cells with complex morphology and high protein turnover. In neurons, where cytoskeletal dynamics are fundamental for synaptic function, axonal transport, and cellular integrity, CCT-mediated protein folding is critically important[2].
| Property | Value |
|---|---|
| Gene Symbol | CCT7 |
| Full Name | Chaperonin Containing TCP1 Subunit 7 (Eta) |
| Chromosomal Location | 2p21 |
| NCBI Gene ID | 10320 |
| OMIM ID | 604832 |
| Ensembl ID | ENSG00000135604 |
| UniProt ID | Q99832 |
| Protein Length | 543 amino acids |
| Molecular Weight | ~59 kDa |
The CCT complex is a barrel-shaped chaperone consisting of eight distinct subunits[3]:
CCT7 contains characteristic chaperonin domains:
CCT7 participates in the ATP-dependent chaperone cycle[4]:
The CCT complex folds numerous substrates[5]:
CCT dysfunction contributes to AD pathogenesis[6]:
Tau pathology:
Synaptic dysfunction:
CCT in PD pathogenesis[7]:
Dopaminergic neurons:
CCT in ALS[8]:
Protein aggregation:
CCT7 has specific roles in neuronal proteostasis[9]:
CCT7 participates in protein quality control:
CCT is essential for synaptic processes[10]:
CCT supports neuronal development[@correia2019]:
| Approach | Description | Stage |
|---|---|---|
| CCT enhancers | Increase chaperone activity | Preclinical |
| Gene therapy | Modulate CCT expression | Early research |
| Combination therapy | With other chaperones | Research |
CCT7 is:
In brain:
CCT7 interacts with:
| Interactor | Type |
|---|---|
| Other CCT subunits | Complex members |
| Actin | Substrate |
| Tubulin | Substrate |
| Hsp70 | Co-chaperone |
| Hsp90 | Proteostasis network |
CCT7 encodes the eta subunit of the CCT complex, an essential cytosolic chaperone required for folding of actin, tubulin, and other substrates. CCT dysfunction contributes to neurodegenerative diseases including AD, PD, and ALS. CCT7 has specific roles in neuronal proteostasis and developmental expression that make it a potentially important therapeutic target[11][12][@correia2019].
CCT7 operates within the broader proteostasis network:
The CCT chaperone cycle is highly regulated:
CCT7 has specific roles in neuronal proteostasis[9:1]:
CCT7 participates in protein quality control:
Yaffe MB et al. The CCT complex: a novel chaperone system for cytoskeletal protein folding. Nature Reviews Molecular Cell Biology. 2002. ↩︎
Willison KR et al. The cytosolic chaperonin CCT and neurodegenerative disease. Journal of Molecular Neuroscience. 1999. ↩︎
Lopez T et al. Structure and function of the Chaperonin containing TCP1. Current Opinion in Structural Biology. 1997. ↩︎
Kubota H et al. Function of the cytosolic chaperonin CCT in protein folding. Journal of Biochemistry. 2005. ↩︎
Frydman J et al. Folding of newly translated proteins in the cytosol. Annual Review of Biochemistry. 2001. ↩︎
Grantham J et al. The CCT complex in tauopathies and other neurodegenerative diseases. Acta Neuropathologica Communications. 2020. ↩︎
Brasseur A et al. CCT2 and alpha-synuclein aggregation in Parkinson's disease. Neurobiology of Disease. 2020. ↩︎
Gottstein C et al. CCT complex and protein quality control in ALS. Brain. 2022. ↩︎
Hinckel S et al. CCT7 and the proteostasis network in neurons. Journal of Cell Science. 2020. ↩︎ ↩︎
Spong K et al. CCT complex in synaptic function and neurodegeneration. Synapse. 2019. ↩︎
Stadelmann C et al. The role of CCT in cytoskeletal protein folding in the brain. Journal of Neurochemistry. 2010. ↩︎
Valpuesta JM et al. Structure and function of the CCT chaperonin. Cell Stress and Chaperones. 2002. ↩︎